Reaction
Alveolitis reporting signals
As of the last recalculation, Alveolitis appears in 1,407 FAERS reports alongside 40 co-occurring drug terms. The strongest observed disproportionality signal is DIMENHYDRINATE (PRR 66.0).
Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.
| Drug | Co-reports | PRR | ROR |
|---|---|---|---|
| Dimenhydrinate | 46 | 66.0 | 66.3 |
| Amiodarone Hydrochloride | 28 | 37.7 | 37.8 |
| Diltiazem Hydrochloride Extended-Release Tablets | 24 | 31.7 | 31.8 |
| Aprepitant | 35 | 28.7 | 28.8 |
| Trastuzumab | 83 | 18.9 | 19.0 |
| Doxorubicin Hydrochloride | 40 | 18.6 | 18.6 |
| Ceftriaxone Sodium | 46 | 18.3 | 18.3 |
| Paclitaxel | 104 | 16.7 | 16.7 |
| Filgrastim | 40 | 16.2 | 16.2 |
| Paclitaxel (Aibumin-Bound) | 84 | 16.0 | 16.0 |
| Dalteparin Sodium | 11 | 15.5 | 15.5 |
| Tamsulosin Hydrochloride | 21 | 15.4 | 15.5 |
| Candesartan Cilexetil | 26 | 14.9 | 14.9 |
| Fosaprepitant Dimeglumine | 11 | 11.9 | 11.9 |
| Rifampicin | 8 | 11.8 | 11.8 |
| Dronedarone | 8 | 11.7 | 11.7 |
| Metoclopramide | 42 | 11.6 | 11.6 |
| Digoxin | 54 | 11.5 | 11.5 |
| Sirolimus | 10 | 11.1 | 11.1 |
| Gemcitabine | 28 | 10.7 | 10.7 |
| Gemcitabine Hydrochloride | 37 | 10.6 | 10.6 |
| Doxorubicin | 56 | 9.6 | 9.6 |
| Ceftriaxone | 20 | 9.1 | 9.1 |
| Bleomycin Sulfate | 6 | 8.6 | 8.6 |
| Pertuzumab | 14 | 7.7 | 7.7 |
| Vemurafenib | 6 | 7.4 | 7.4 |
| Sevoflurane | 4 | 7.1 | 7.1 |
| Crizotinib | 6 | 7.0 | 7.0 |
| Lapatinib | 7 | 6.7 | 6.7 |
| Brivaracetam | 4 | 6.6 | 6.6 |
| Gefitinib | 4 | 6.6 | 6.6 |
| Docetaxel Anhydrous | 25 | 5.6 | 5.6 |
| Docetaxel | 25 | 5.6 | 5.6 |
| Pemetrexed Disodium | 13 | 5.1 | 5.1 |
| Dabrafenib | 7 | 4.9 | 4.9 |
| Erlotinib | 3 | 4.6 | 4.6 |
| Abiraterone | 4 | 4.4 | 4.4 |
| Atezolizumab | 11 | 4.2 | 4.2 |
| Ipilimumab | 12 | 4.1 | 4.1 |
| Abiraterone Acetate | 9 | 3.2 | 3.3 |